Mineralys Therapeutics, Inc. (MLYS) Cash Flow Statement
Mineralys Therapeutics, Inc. (MLYS) generated -$138.8M of operating cash flow over the twelve months to 2026-06-30, spent $15000 on capital expenditure and had free cash flow of -$138.8M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
MLYSMineralys Therapeutics, Inc.Follow MLYS — free
—
Price chart with a free account
- Market cap
- 1.8B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 16 Nov, in 23 days
| Line | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|
| Operating cash flow | -81.2 | -166.3 | -142.4 | -138.8 | |
| Capital expenditure | — | 0.1 | 0.0 | -0.0 | |
| Free cash flow | — | -166.4 | -142.4 | -138.8 | |
| Stock-based compensation | 5.1 | 11.3 | 19.3 | — |
USD millions · SEC XBRL
Mineralys Therapeutics, Inc. — questions
- What is Mineralys Therapeutics, Inc.'s operating cash flow?
- -$138.8M over the twelve months to 2026-06-30.
- How much does Mineralys Therapeutics, Inc. spend on capital expenditure?
- $15000 over the twelve months to 2026-06-30.
- What is Mineralys Therapeutics, Inc.'s free cash flow?
- -$138.8M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from Mineralys Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.